Invitris

Winter 2023Active

Creating new protein-based drugs at scale

Save

Invitris

Winter 2023Active

Creating new protein-based drugs at scale

Save

Company details

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.

Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Location

Munich, BY, Germany

Founded

Unknown

Request the Invitris report.

Invitris has no report yet. Sign in with your email to request one.